Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.48 |
| ▸ | FLT1 | P17948 | 11/20 | 0.48 |
| ▸ | MET | P08581 | 3/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749151 | 1.00 | KDR (0.48) | KDRFLT1METSCN9AADORA3 | |
| SCHEMBL6749154 | 1.00 | KDR (0.48) | KDRFLT1METSCN9AADORA3 | |
| SCHEMBL6687875 | 0.94 | KDR (0.46) | KDRFLT1METSCN9AADORA3 | |
| SCHEMBL6664885 | 0.93 | KDR (0.47) | KDRFLT1METSCN9AADORA3 | |
| SCHEMBL6664180 | 0.92 | KDR (0.47) | KDRFLT1METSCN9AADORA3 | |
| SCHEMBL6750890 | 0.92 | KDR (0.47) | KDRFLT1MET | |
| SCHEMBL6750891 | 0.92 | KDR (0.47) | KDRFLT1MET | |
| SCHEMBL6660904 | 0.92 | KDR (0.47) | KDRFLT1MET | |
| SCHEMBL6747209 | 0.91 | KDR (0.49) | KDRFLT1METSCN9AADORA3 | |
| SCHEMBL6749144 | 0.91 | KDR (0.49) | KDRFLT1METSCN9AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833456-B2 | Heterocyclic sulfides such as 5-(2-(2R-Hydroxymethyl-pyrrolidine-1-carbonyl)-thieno(3,2-b)pyridin-7 -ylamino)-2-methyl-indole-1-carboxylic acid methylamide, used as angiogenesis inhibitors | AGOURON PHARMACEUTICALS, INC. | 2004-12-21 | — | — | US | disclosed |
| US-20040019065-A1 | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use | ROMINES WILLIAM HENRY (US) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019065-A1 | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use | CDKN1A, CCNA1, TYMP | KDR 62/4885FLT1 12/4885MET 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.